Vertex said Phase 2b results showed inaxaplin reduced a urine-protein measure in two groups with APOL1-mediated kidney disease; Amgen said a Phase 3 trial found dazodalibep reduced Sjögren’s disease activity. Their Q2 revenues rose year over year by 12% and 10%, respectively.
Inaxaplin reduced the urine albumin-to-creatinine ratio in both studied groups: patients with APOL1-mediated kidney disease (AMKD) and modest proteinuria, and patients with AMKD and type 2 diabetes. It is also in a Phase 2/3 study of AMKD patients with severe proteinuria; the article says approval remains a long way off. Vertex could also receive approval for povetacicept for IgA nephropathy by the end of November. The Motley Fool’s investment case cites Vertex’s effort to diversify beyond cystic fibrosis.
Amgen’s Q2 revenue reached $10.1 billion, up 10% year over year. Management said 22 products posted sales growth of at least 10%, and 17 had annualized revenue run rates above $1 billion, while denosumab sales fell amid U.S. biosimilar competition. Amgen is also testing MariTide for obesity and related conditions in several Phase 3 trials; it could be dosed monthly or less often. Some analysts expect dazodalibep to generate well over $1 billion in peak sales.
